Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.4 (
trypsin
)
42,187
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Changes in protease sensitivity of extracellular loop two (
EL2
) of the dopamine transporter (DAT) during inhibitor and substrate binding were examined using
trypsin
proteolysis and epitope-specific immunoblotting. In control rat striatal membranes, proteolysis of DAT in a restricted region of
EL2
was produced by 0.001 to 10 microg/ml
trypsin
. However, in the presence of the dopamine uptake blockers [2-(diphenylmethoxyl) ethyl]-4-(3phenylpropyl) piperazine (GBR 12909), mazindol, 2beta-carbomethoxy-3beta-(4-flourophenyl)tropane (beta-CFT), nomifensine, benztropine, or (-)-cocaine, 100- to 1000-fold higher concentrations of
trypsin
were required to produce comparable levels of proteolysis. Protease resistance induced by ligands was correlated with their affinity for DAT binding, was not observed with Zn2+, (+)-cocaine, or inhibitors of norepinephrine or serotonin transporters, and was not caused by altered catalytic activity of
trypsin
. Together, these results support the hypothesis that the interaction of uptake inhibitors with DAT induces a protease-resistant conformation in
EL2
. In contrast, binding of substrates did not induce protease resistance in
EL2
, suggesting that substrates and inhibitors interact with DAT differently during binding. To assess the effects of
EL2
proteolysis on DAT function, the binding and transport properties of
trypsin
-digested DAT were assayed with [3H]CFT and [3H]dopamine. Digestion decreased the Bmax for binding and the Vmax for uptake in amounts that were proportional to the extent of proteolysis, indicating that the structural integrity of
EL2
is required for maintenance of both DAT binding and transport functions. Together this data provides novel information about inhibitor and substrate interactions at
EL2
, possibly relating the protease resistant DAT conformation to a mechanism of transport inhibition.
...
PMID:Uptake inhibitors but not substrates induce protease resistance in extracellular loop two of the dopamine transporter. 1497 48